From Richard Batt, Shadforth Financial Group.
Prima Biomed (PRR)
PRR focuses on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. The technology is interesting in that it uses the body’s own processes to destroy cancer cells, reducing the side-effects compared to external chemotherapy agents. There’s several potential near-term catalysts for the stock, including the successful conclusion of clinical trials. Any good news should be positive for the share price.
Good to see PRR is on the radar and being promoted.
tip in the bull newsletter
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
-0.015(4.41%) |
Mkt cap ! $476.3M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.484M | 4.550M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 117897 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 160773 | 21 |
View Market Depth
| Last trade - 15.55pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |